Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) about the decision to grant their patent for drug compositions for the elimination of bacterial promoters of colorectal cancer through intraluminal application (RNX-051). Today's announcement signifies a significant milestone as the EPO has approved EP patent application No. 3740286, encompassing Reponex's innovative treatment method.

This method focuses on the removal of the bacterial layer, also known as biofilm, which shields cancerous growths in the colon or rectum. By removing this protective barrier, the treatment aims to render cancer cells more susceptible to the body's natural immune defenses. Colorectal cancer poses a significant global challenge.

According to the World Health Organization (WHO) and The International Agency for Research on Cancer (IARC), the global market for colorectal cancer was estimated at USD 9.4 billion in 2020. Therefore, the need for innovative treatment methods is more urgent than ever. The patent is valid until 2039.

With the attainment of full Supplementary Protection Certificate (SPC) extension, the validity will extend until 2044.